A detailed history of Marshall Wace, LLP transactions in Alvotech stock. As of the latest transaction made, Marshall Wace, LLP holds 33,213 shares of ALVO stock, worth $395,566. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,213
Previous 38,992 14.82%
Holding current value
$395,566
Previous $474,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.76 - $12.99 $62,182 - $75,069
-5,779 Reduced 14.82%
33,213 $395,000
Q2 2024

Aug 14, 2024

SELL
$11.4 - $14.51 $2.41 Million - $3.06 Million
-211,131 Reduced 84.41%
38,992 $474,000
Q1 2024

May 15, 2024

BUY
$11.36 - $17.27 $2.84 Million - $4.32 Million
250,123 New
250,123 $3.06 Million

Others Institutions Holding ALVO

About Alvotech


  • Ticker ALVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 248,650,000
  • Market Cap $2.96B
  • Description
  • Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...
More about ALVO
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.